In two weeks the 2015 meeting of the American Society of Clinical Oncology (ASCO) will take place in Chicago, bringing oncology professionals together from around the world. Below are the abstracts Lymphoma Program team members were involved in whole or in part to be presented at ASCO 2015:
Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials
Waldenstrom’s Macroglobulinemia
Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM)
Please look to this space for further updates about developments in ASCO 2015.